L. McAllister

Targeted agents or immuno-oncology therapies as first-line therapy for BRAF-mutated metastatic melanoma: a real-world study.

J. Luke, B. Feinberg, J. Kish, 2019, Future oncology.

Clinical benefit of treatment with eribulin mesylate for metastatic triple‐negative breast cancer: Long‐term outcomes of patients treated in the US community oncology setting

B. Feinberg, J. Kish, S. Mougalian, 2018, Cancer medicine.